Transcode Therapeutics, Inc. - Common Stock (RNAZ) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
RNAZ on Nasdaq
Shares outstanding
849,000
Price per share
$6.44
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
14,426
Total reported value
$155,012
% of total 13F portfolios
0%
Share change
-15,956
Value change
-$83,211
Number of holders
7
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Transcode Therapeutics, Inc. - Common Stock (RNAZ) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CK Life Sciences Intl (Holdings) Inc 9.1% 0% $871,161 83,285 0% CK Life Sciences Int'l., (Holdings) Inc. 27 Oct 2025
SABBY MANAGEMENT, LLC 4.9% $433,482 41,601 SABBY MANAGEMENT, LLC 31 Dec 2025
GOLDMAN SACHS GROUP INC 0% -98% $858 -$511,871 82 -100% THE GOLDMAN SACHS GROUP, INC. 30 Sep 2025

As of 30 Sep 2025, 7 institutional investors reported holding 14,426 shares of Transcode Therapeutics, Inc. - Common Stock (RNAZ). This represents 1.7% of the company’s total 849,000 outstanding shares.

Institutional Holders of Transcode Therapeutics, Inc. - Common Stock (RNAZ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 14,426 $155,012 -$83,211 $10.75 7
2025 Q2 30,382 $236,981 +$236,981 $7.80 8